tirzepatide for fibromyalgia as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis It's important to study the

Theory 1: Glucagon Receptor Activation Retatrutide is the ONLY obesity medication activating glucagon receptors Glucagon affects peripheral nerves and nerve signaling May alter nerve sensitivity temporarily Theory 2: Rapid Metabolic Changes 28.7% weight loss at 68 weeks = very rapid Rapid fat loss changes nerve compression (fat pads around nerves) Metabolic shifts affect nerve function Theory 3: Both Combination of direct glucagon effects + metabolic changes Explains why incidence is dose-dependent (20.9% @ 12mg, 8.8% @ 9mg) Is Dysesthesia Dangerous

Disclaimer This compounded medication contains Tirzepatide combined with glycine and vitamin B12, and is formulated specifically for individual patients who may not tolerate standard formulations or who require a customized therapeutic approach

The combination of exercise-induced heart rate elevation plus stimulant effects may feel uncomfortable and potentially stress the cardiovascular system unnecessarily

The SELECT trial established semaglutide as the first obesity drug to demonstrate cardiovascular risk reduction in a dedicated outcomes trial